In:
Journal of Diabetes Research, Hindawi Limited, Vol. 2018 ( 2018), p. 1-11
Kurzfassung:
Experimental evidence in mice suggests a role for interleukin- (IL-) 13 in insulin resistance and low-grade systemic inflammation. However, IL-13 serum levels have not been assessed in subjects with insulin resistance, and associations of IL-13 with parameters of low-grade systemic inflammation are still unknown. Our main goal was to examine the systemic levels of IL-13 in patients with insulin resistance, while also studying the relationship of IL-13 with anthropometric, metabolic, and low-grade systemic inflammatory markers. Ninety-two participants were included in the study and divided into insulin-resistant patients and noninsulin-resistant controls. Blood levels of IL-13, glucose, insulin, triglycerides, cholesterol, tumor necrosis factor-alpha (TNF- α ), IL-10, proinflammatory (Mon-CD11c + CD206 − ), and anti-inflammatory (Mon-CD11c − CD206 + ) monocytes, as well as anthropometric parameters, were measured in all volunteers. Insulin-resistant patients showed 2.5-fold higher serum levels of IL-13 than controls ( P 〈 0.0001 ) and significantly increased values of TNF- α and Mon-CD11c + CD206 − , with concomitant reductions in IL-10 and Mon-CD11c − CD206 + . Increased IL-13 was extraordinarily well associated with hyperglycemia ( r = 0.7362 ) and hypertriglyceridemia ( r = 0.7632 ) but unexpectedly exhibited no significant correlations with TNF- α ( r = 0.2907 ), IL-10 ( r = − 0.3882 ), Mon-CD11c + CD206 − ( r = 0.2745 ) or Mon-CD11c − CD206 + ( r = − 0.3237 ). This study demonstrates that IL-13 serum levels are elevated in patients with insulin resistance without showing correlation with parameters of low-grade systemic inflammation.
Materialart:
Online-Ressource
ISSN:
2314-6745
,
2314-6753
DOI:
10.1155/2018/7209872
Sprache:
Englisch
Verlag:
Hindawi Limited
Publikationsdatum:
2018
ZDB Id:
2711897-6